Highlight
1. Oral semaglutide lowers major adverse cardiovascular events (MACE) risk by 14% in patients with type 2 diabetes and cardiovascular or kidney disease.
2. The cardiovascular benefit of oral semaglutide is consistent regardless of baseline or in-trial use of SGLT2 inhibitors.
3. Safety profiles of oral semaglutide with or without SGLT2 inhibitors were similar, supporting combined therapy safety.
4. Results affirm oral semaglutide as a valuable therapeutic option in high cardiovascular risk diabetes populations.
